The multicentric retrospective BIO-Ra study combined inflammatory indices from peripheral blood and clinical factors in a composite prognostic score for metastatic castration-resistant prostate cancer patients receiving Radium-223 (Ra-223). In the present study, we evaluated (i) theprognostic power of the BIO-Ra score in the framework of the restricted use of Ra-223 promoted by the European Medicines Agency in 2018; (ii) the treatment completion prediction of the BIO-Ra score. Four hundred ninety-four patients from the BIO-Ra cohort were divided into three risk classes according to the BIO-Ra score to predict the treatment completion rate (p < 0.001 among all the three groups). Patients receiving Ra-223 after restriction (89/494) were at later stages of the disease compared with the pre-restriction cohort (405/494), as a higher percentage of BIO-Ra high-risk classes (46.1% vs. 34.6%) and lower median Overall survival (12.4 vs. 23.7 months, p < 0.001) was observed. Despite this clinically relevant difference, BIO-Ra classes still predicted divergent treatment completion rates in the post-restriction subgroup (72%, 52.2%, and 46.3% of patients belonging to low-, intermediate-, and high-risk classes, respectively). Although the restricted use has increased patients at higher risk with unfavourable outcome after Ra-223 treatment, the BIO-Ra score maintains its prognostic value.

Prognostic value of the BIO-Ra Score in metastatic castration-resistant prostate cancer patients treated with Radium-223 after the European Medicines Agency restricted use: secondary investigations of the multicentric BIO-Ra study / Bauckneht, Matteo; Elena Rebuzzi, Sara; Ponzano, Marta; Borea, Roberto; Signori, Alessio; Frantellizzi, Viviana; Lodi Rizzini, Elisa; Mascia, Manlio; Lavelli, Valentina; Miceli, Alberto; De Feo, Maria Silvia; Rosario Pisani, Antonio; Nuvoli, Susanna; Tripoli, Vincenzo; Giuseppe Morganti, Alessio; Mammucci, Paolo; Caponnetto, Salvatore; Mantica, Guglielmo; Domenico Di Nicola, Angelo; Villano, Carlo; Cindolo, Luca; Morbelli, Silvia; Sambuceti, Gianmario; Fanti, Stefano; Patrizio Costa, Renato; Spanu, Angela; Rubini, Giuseppe; Monari, Fabio; De Vincentis, Giuseppe; Fornarini, Giuseppe. - In: CANCERS. - ISSN 2072-6694. - 14:7(2022). [10.3390/cancers14071744]

Prognostic value of the BIO-Ra Score in metastatic castration-resistant prostate cancer patients treated with Radium-223 after the European Medicines Agency restricted use: secondary investigations of the multicentric BIO-Ra study

Viviana Frantellizzi;Maria Silvia De Feo;Salvatore Caponnetto;Giuseppe De Vincentis
Penultimo
;
2022

Abstract

The multicentric retrospective BIO-Ra study combined inflammatory indices from peripheral blood and clinical factors in a composite prognostic score for metastatic castration-resistant prostate cancer patients receiving Radium-223 (Ra-223). In the present study, we evaluated (i) theprognostic power of the BIO-Ra score in the framework of the restricted use of Ra-223 promoted by the European Medicines Agency in 2018; (ii) the treatment completion prediction of the BIO-Ra score. Four hundred ninety-four patients from the BIO-Ra cohort were divided into three risk classes according to the BIO-Ra score to predict the treatment completion rate (p < 0.001 among all the three groups). Patients receiving Ra-223 after restriction (89/494) were at later stages of the disease compared with the pre-restriction cohort (405/494), as a higher percentage of BIO-Ra high-risk classes (46.1% vs. 34.6%) and lower median Overall survival (12.4 vs. 23.7 months, p < 0.001) was observed. Despite this clinically relevant difference, BIO-Ra classes still predicted divergent treatment completion rates in the post-restriction subgroup (72%, 52.2%, and 46.3% of patients belonging to low-, intermediate-, and high-risk classes, respectively). Although the restricted use has increased patients at higher risk with unfavourable outcome after Ra-223 treatment, the BIO-Ra score maintains its prognostic value.
File allegati a questo prodotto
File Dimensione Formato  
Bauckneht_Prognostic value_2022.pdf

accesso aperto

Note: https://www.mdpi.com/2072-6694/14/7/1744
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1 MB
Formato Adobe PDF
1 MB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1627789
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact